Luke Boulter
Edinburgh, SCT, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 63 publications
Opening the Flood Gates: Epigenetic Regulators Safeguard Against Rogue Lineage Plasticity in Cholangiocarcinoma.
Journal: Cellular and molecular gastroenterology and hepatology
Published: February 10, 2026
Tissues assemble! Rebuilding the human periportal liver in a dish.
Journal: Cell stem cell
Published: January 27, 2026
The instructive scar - the dynamic role of extracellular matrix in biliary pathophysiology.
Journal: Disease models & mechanisms
Published: January 21, 2026
Conserved Phosphoprotein Networks Identify Actionable Adhesion/Wnt and Metallothionein Modules in Cholangiocarcinoma.
Journal: Medical sciences (Basel, Switzerland)
Published: December 24, 2025
Integrative Sequencing and Proteogenomic Approaches to Intratumoral Heterogeneity in Cholangiocarcinoma: Implications for Precision Diagnosis and Therapy.
Journal: Medical sciences (Basel, Switzerland)
Published: December 02, 2025
Cholangiocarcinoma 2026: status quo, unmet needs and priorities.
Journal: Nature reviews. Gastroenterology & hepatology
Published: October 31, 2025
Modulating Wnt/β-catenin pathway activity to enhance chemosensitivity in cholangiocarcinoma.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: April 01, 2025
Proteomic profiling reveals common and region-specific protein signatures underlying tumor heterogeneity in cholangiocarcinoma.
Journal: Scientific reports
Published: January 05, 2025
Whole exome sequencing of multi-regions reveals tumor heterogeneity in Opisthorchis viverrini-associated cholangiocarcinoma.
Journal: Scientific reports
Published: November 10, 2024
Semaphorin 7a is protective through immune modulation during acetaminophen-induced liver injury.
Journal: Journal of inflammation (London, England)
Published: October 04, 2024
Mitochondrial genomic alterations in cholangiocarcinoma cell lines.
Journal: PloS one
Published: September 23, 2024
Targeting protein hyper-SUMOylation halts cholangiocarcinoma progression by impairing cancer cell viability and tumor-stroma cross talk.
Journal: Hepatology (Baltimore, Md.)
Published: September 12, 2024
Last Updated: 09/26/2026